Natco Pharma shares slipped 1.5% to ₹871 on Tuesday as the company disclosed four U.S. FDA observations at its Visakhapatnam facility. Alongside this regulatory update, the firm increased its stake in U.S.-based biotech company eGenesis to $22 million, focusing on long-term gene-edited organ research.
Natco Pharma shares fell approximately 1.5 percent to ₹871 on Tuesday, August 25, as investors weighed a combination of regulatory scrutiny and strategic corporate updates. The company disclosed that the U.S. Food and Drug Administration (FDA) issued a Form 483 with four observations following an inspection of its finished dosage formulations facility in Visakhapatnam, Andhra Pradesh, which took place between August 17 and August 21, 2026.
A Form 483 is issued when investigators identify conditions that may constitute violations of the Food Drug and Cosmetic Act. The company has stated that it considers these observations to be procedural and is working to address them within the required timelines. For pharmaceutical companies, regulatory compliance is critical as any delays in clearing observations can potentially impact the approval of new products or the smooth operation of export facilities to the U.S. market.
While the market responded to the regulatory news, Natco Pharma also announced a fresh investment of $14 million in eGenesis, a U.S.-based biotechnology company. This brings Natco’s total investment in the firm to $22 million. The funding is being routed through the company's subsidiaries using convertible promissory notes, which carry an 8 percent annual compound interest rate.
eGenesis is a clinical-stage company focused on gene editing and genome engineering for transplantable organs, targeting complex medical needs such as kidney, liver, and heart transplantation. This investment is part of Natco’s long-term strategy to back early-stage research in healthcare. However, because eGenesis is currently pre-revenue, this capital allocation represents a long-term risk and does not provide immediate financial returns for the company.
Investors are also tracking the company's recent financial performance, which may be influencing market sentiment. Natco Pharma reported a consolidated net profit of ₹207 crore for the first quarter of fiscal year 2027, marking a 57 percent decline compared to the same period in the previous year. This significant drop in profitability highlights the challenges the company has faced in maintaining margins.
The key focus for shareholders in the coming months will be the company’s ability to resolve the FDA observations at its Visakhapatnam plant without significant delays. Additionally, investors will be monitoring the progress of the eGenesis therapeutic programs and whether the company can stabilize its profit margins in subsequent quarters after the recent sharp decline.